Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. (Q51815713)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 May 2013

Language	Label	Description	Also known as
English	Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.	scientific article published on 30 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. (English)

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

author name string

Ki-Seong Eom

1

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Seung-Hwan Shin

2

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Jae-Ho Yoon

3

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Seung-Ah Yahng

4

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Sung-Eun Lee

5

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Byung-Sik Cho

6

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Yoo-Jin Kim

7

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Hee-Je Kim

8

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Chang-Ki Min

9

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Dong-Wook Kim

10

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Jong-Wook Lee

11

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Woo-Sung Min

12

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Chong-Won Park

13

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Seok Lee

14

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

publication date

30 May 2013

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

American Journal of Hematology

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

88

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

8

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

634-641

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23465

21 January 2018

Identifiers

10.1002/AJH.23465

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

release_u6xb7wuyrjfgrjbspztfuvx5b4

1 reference

https://api.fatcat.wiki/v0/release/u6xb7wuyrjfgrjbspztfuvx5b4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/23620000

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51815713&oldid=1844399116"